Sarah L Gerdeman, LCSW-R, LICSW in Burlington, VT - Medicare Provider

Sarah L Gerdeman, LCSW-R, LICSW is a medicare enrolled "Social Worker - Clinical" provider in Burlington, Vermont. Her current practice location is 617 Riverside Ave, Burlington, Vermont. You can reach out to her office (for appointments etc.) via phone at (802) 864-6309.

Sarah L Gerdeman is licensed to practice in Vermont (license number 0890074344) and she also participates in the medicare program. She accepts medicare assignments (which means she accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance) and her NPI Number is 1023008935.

Contact Information

	Sarah L Gerdeman, LCSW-R, LICSW
	617 Riverside Ave, Burlington, VT 05401-1601
	(802) 864-6309
	Not Available

Healthcare Provider's Profile

Full Name	Sarah L Gerdeman
Gender	Female
Speciality
Experience	Years
Location	617 Riverside Ave, Burlington, Vermont
Accepts Medicare Assignments	Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance.

Medical Education and Training:

Sarah L Gerdeman attended and graduated from in

NPI Data:

NPI Number: 1023008935
Provider Enumeration Date: 10/24/2005
Last Update Date: 05/31/2012

Medicare PECOS Information:

PECOS PAC ID:
Enrollment ID:

Medical Identifiers

Medical identifiers for Sarah L Gerdeman such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1023008935	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
101YM0800X	Counselor - Mental Health	057211-1 (New York)	Secondary
1041C0700X	Social Worker - Clinical	0890074344 (Vermont)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Sarah L Gerdeman is enrolled with medicare and thus, if eligible, can prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Sarah L Gerdeman, LCSW-R, LICSW 617 Riverside Ave, Burlington, VT 05401-1601 Ph: (802) 864-6309	Sarah L Gerdeman, LCSW-R, LICSW 617 Riverside Ave, Burlington, VT 05401-1601 Ph: (802) 864-6309

News Archive

Spectral announces license agreement with Bio-Rad Pasteur S.A.

Spectral Diagnostics Inc. has announced that it has entered into a non-exclusive license and material supply agreement with Bio-Rad Pasteur S.A., a leader in the manufacturing and distribution of a broad range of products for the life science research and clinical diagnostics markets.

Simoni Lift minimally invasive surgery to be revealed at international facial cosmetic surgery symposium

Renowned surgeons and aesthetic practitioners from around the world will be gathering to share and discuss the latest techniques and technologies in cosmetic surgery and dermatology at The 6th Annual Facial Cosmetic Surgery International Multi-Specialty Symposium in Las Vegas, July 14-18. For the first time, Beverly Hills Facial Plastic Surgeon Payman Simoni, MD, FACS, will be revealing the highly specialized techniques he has perfected with his highly publicized Simoni Lift™.

"Crisis Response" is the motto of the 2021 Local Health Authority Day

Coping with the pandemic is a task for the society as a whole. In this connection, the around 400 municipal health authorities are a central pillar for the protection of public health in Germany.

COVID-19 modeling shows that social distancing is a must, must, must

A new study shows that using mathematical modeling and accounting for several factors such as age distribution and density of the population, a clearer picture of COVID-19 infection in a population could be gained. The study titled, "Level of under-reporting including under-diagnosis before the first peak of COVID-19 in various countries: Preliminary Retrospective Results Based on Wavelets and Deterministic Modeling," is published as an accepted manuscript in the journal Infection Control & Hospital Epidemiology.

Celsion recommended to continue patient enrollment in its ThermoDox Phase III liver cancer trial

Celsion Corporation (NASDAQ:CLSN) announced today the Data Safety Monitoring Board ("DSMB") has reviewed the safety data from the first group of patients enrolled in its pivotal ThermoDox® Phase III clinical trial for primary liver cancer ("HEAT study") and has recommended that Celsion continue to enroll patients in the trial.

Sarah L Gerdeman, LCSW-R, LICSW - Medicare Counselor in Burlington, VT